AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Delta(14)-sterol reductase TM7SF2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O76062

UPID:

ERG24_HUMAN

Alternative names:

3-beta-hydroxysterol Delta (14)-reductase; Another new gene 1 protein; C-14 sterol reductase; Putative sterol reductase SR-1; Sterol C14-reductase; Transmembrane 7 superfamily member 2

Alternative UPACC:

O76062; A8K4H0; O95982; Q8IY06; Q96E64; Q96GZ1

Background:

Delta(14)-sterol reductase TM7SF2, known by alternative names such as 3-beta-hydroxysterol Delta(14)-reductase and Sterol C14-reductase, plays a crucial role in cholesterol biosynthesis. It catalyzes the reduction of the C14-unsaturated bond of lanosterol, a key step in the metabolic pathway leading to cholesterol production. This enzyme's activity is essential for maintaining cellular cholesterol levels and overall cell membrane integrity.

Therapeutic significance:

Understanding the role of Delta(14)-sterol reductase TM7SF2 could open doors to potential therapeutic strategies. Its pivotal function in cholesterol biosynthesis makes it a target for developing treatments aimed at regulating cholesterol levels, potentially addressing conditions related to cholesterol imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.